Diagnostic study demonstrates PDGFRA immunohistochemistry accurately detects gene amplification in central nervous system tumors, supporting routine antibody testing.
PDGFRA gene amplification is now recognized as a diagnostically and prognostically relevant molecular alteration in central nervous system tumors. Herein, we demonstrated that PDGFRA immunohistochemistry is a highly specific and sensitive biomarker for identifying PDGFRA amplification and should be part of the neuropathologist's routine panel of antibodies.
No takes yet. Share an insight, caveat, or question.
Tauziède‐Espariat et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: